Wednesday, December 7, 2022

New Study Outlines Breakthrough in Diagnosing Acute Infections by Reading the Immune System

Inflammatix Reports Study Published in Nature Communications

“When seeing a sick patient with a suspected infection in the emergency room, most physicians are forced to basically make an educated guess about whether the patient has a bacterial or viral infection, and then treat accordingly. Unfortunately, despite best efforts, this guessing game can have terrible outcomes for patients and for our health system,” said Tim Sweeney, M.D., Ph.D., co-founder and chief executive officer of Inflammatix.

“For 20 years, researchers have been looking for a way to use transcriptomics – the study of the body’s gene expression – to classify patients with acute infections. To date, others’ attempts to apply machine learning to this problem have not held up when applied to diverse patient populations. Our new study is the first time that a locked, multi-gene signature has been validated in a blinded, independent clinical cohort. It represents a major technical breakthrough in translating our tests to the clinic.”

For the new publication, Inflammatix and Stanford University scientists applied advanced machine learning to develop a 29-gene classifier (“BVN-1”) that can identify bacterial, viral or no infections across 1,069 blood samples from 18 prior studies of patients diagnosed with acute infections. The patients represented a wide range of geographic regions, clinical care setting, and disease contexts.

The researchers then tested the locked classifier – i.e., without modification or retraining – on an independent cohort of 109 patients from Stanford University’s intensive care unit who underwent evaluation for acute infection and sepsis. They found that the test was highly accurate in diagnosing infections, especially among patients tested within 36 hours of hospital admission – a critical time for determining treatment. Among this subset, the test demonstrated an AUROC of 0.92 (95% CI; 0.83-0.99) for identifying patients with bacterial infections and 0.91 (95% CI; 0.82-0.98) for viral infections.

The molecular classifier also demonstrated higher accuracy than standard biomarkers — procalcitonin (PCT) and C-reactive protein (CRP) – that have been associated with acute infections and sepsis. Among the subset of patients with PCT and CRP results in the Stanford ICU cohort, the Inflammatix test had an AUROC of 0.87 (95% CI; 0.8-0.94) for bacterial infections, compared to 0.83 (95% CI; 0.75-0.92) for PCT and 0.70 (95% CI; 0.6-.081) for CRP. Neither PCT nor CRP could positively identify viral infections.

“To wit, 100 percent of the patients in this cohort were on antibiotics, but many did not have an underlying bacterial infection. Improved diagnostics would benefit patients and have a major impact on the healthcare system,” said Dr. Sweeney.

“Furthermore, our machine learning team has demonstrated the power of our computational platform in a highly heterogeneous and difficult field. We look forward to bringing the same computational tools to bear across multiple other infectious and inflammatory diseases.”

Antibiotic resistance and sepsis lead to more than 700,0001 and 5 million2 respective deaths worldwide each year. Inflammatix’s HostDx Sepsis and HostDx Fever tests use proprietary machine learning algorithms that incorporate the expression of multiple immune genes (host response) to identify the presence of bacterial or viral infections and to determine if a patient has or is likely to develop sepsis. Inflammatix’s simple-to-use, sample-to-answer HostDx system is designed to produce results at or near the point of care in 30 minutes or less. The company plans to advance its HostDx tests through commercial launch in Europe and submission to the United States Food and Drug Administration in 2021.

In January 2020, Inflammatix announced it had received $32 million in Series C financing. Prior to that, in November 2019, the company announced a cost-sharing contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, to further develop its HostDx tests. The agreement is worth up to $72 million based on achieving certain milestones.*

Citation and Reference

Mayhew, MB et al. A generalizable 29-mRNA neural-network classifier for acute bacterial and viral infections. Nature Communications, 2020.

1 Interagency Coordination Group on Antimicrobial Resistance. No Time to Wait: Securing the Future from Drug-Resistant Infections; Report to the United Nations. April 2019.
2 Rudd KE, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. Lancet 2020; 395:200-211.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.
Subscribe to Medical Device News Magazine

Medtronic Completes Enrollment in Pivotal Trial Evaluating First-of-its-kind Pulsed Field Ablation Catheter for Patients with AFIB

The Sphere-9 catheter combines mapping, navigation, and therapeutic capabilities and is the only catheter capable of delivering both RF and PF energies for ablation, providing physicians with the ability to customize treatment based on a patient's needs during an ablation procedure advises Medtronic.

Bone Health Technologies announces positive Topline Results from Groundbreaking Pivotal Trial of Non-pharmacological Treatment for Osteopenia

The trial by Bone Health Technologies was conducted in partnership with Laura Bilek, Ph.D., the Associate Dean for Research in the College of Allied Health Professions at the University of Nebraska Medical Center (UNMC) and expert in clinical research for the treatment of low bone mass.

Covalon’s SurgiClear Dressing Plays an Important Part in Preventing Surgical Wound Infections at Top Children’s Hospital

Jeremy Harman, PA-C, an author of the study, commented, "The trifecta of breathable barrier protection, antimicrobials, and the ability to monitor the site is what makes this a great dressing. It's easier for us to assess the wound and is more comfortable for patients."

By using this website you agree to accept Medical Device News Magazine Privacy Policy